The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma

Yehuda Z. Patt, Evan M Hersh, Larry A. Schafer, Terry L. Smith, Michael A. Burgess, Jordan U. Gutterman, Allan L. Goldstein, Giora M. Mavligit

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In an attempt improve the response to BCG or BCG + DTIC therapy in Stage IIIB melanoma patients, we added thymosin treatment with repeated doses of 4 mg/m<sup>2</sup> or 40 mg/m<sup>2</sup>. Twenty-eight patients were clinically and immunologically evaluable. Pretreatment immunological evaluation consisted of determination of delayed-type hypersensitivity to recall antigens, enumeration of E-rosettes in blood, and measurement of blood lymphocyte response to phytohemmagglutinin (PHA) and concanavalin A (Con-A). The disease-free interval was correlated with thymosin dose and parameters of immunocompetence. Immunocompetent melanoma patients treated with a high thymosin dose and BCG relapsed earlier than those treated with a low thymosin dose and BCG. Thus, 72% of the melanoma patients who had a PHA SI≥50 and were treated with 4 mg thymosin/m<sup>2</sup>, were disease-free at 9 months, compared with only 31% of those treated with 40 mg/m<sup>2</sup> (P=0.02). When the dermatophytin delayed hypersensitivity response (>10 mm induration) was used as a parameter of immunocompetence, 86% of the patients treated with 4 mg/m<sup>2</sup>, were disease-free at 9 months, as against 28% of patients treated with 40 mg thymosin/m<sup>2</sup> (P=0.07). None of the immunoincompetent patients on high thymosin dose relapsed (0/3). The results suggest that while a high thymosin dose (40 mg/m<sup>2</sup>) may be detrimental to immunocompetent patients, it may have a beneficial effect in immunoincompetent patients. A low thymosin dose is probably not detrimental to immunocompetent melanoma patients in this study. Monitoring of the immune status prior to and during the use of thymosin in cancer immunotherapy is mandatory.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalCancer Immunology, Immunotherapy
Volume7
Issue number2
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Thymosin
Melanoma
Mycobacterium bovis
Immunocompetence
Delayed Hypersensitivity
Immunologic Monitoring
Dacarbazine
Concanavalin A
Immunotherapy
Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Patt, Y. Z., Hersh, E. M., Schafer, L. A., Smith, T. L., Burgess, M. A., Gutterman, J. U., ... Mavligit, G. M. (1979). The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma. Cancer Immunology, Immunotherapy, 7(2), 131-136. https://doi.org/10.1007/BF00205335

The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma. / Patt, Yehuda Z.; Hersh, Evan M; Schafer, Larry A.; Smith, Terry L.; Burgess, Michael A.; Gutterman, Jordan U.; Goldstein, Allan L.; Mavligit, Giora M.

In: Cancer Immunology, Immunotherapy, Vol. 7, No. 2, 1979, p. 131-136.

Research output: Contribution to journalArticle

Patt, YZ, Hersh, EM, Schafer, LA, Smith, TL, Burgess, MA, Gutterman, JU, Goldstein, AL & Mavligit, GM 1979, 'The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma', Cancer Immunology, Immunotherapy, vol. 7, no. 2, pp. 131-136. https://doi.org/10.1007/BF00205335
Patt, Yehuda Z. ; Hersh, Evan M ; Schafer, Larry A. ; Smith, Terry L. ; Burgess, Michael A. ; Gutterman, Jordan U. ; Goldstein, Allan L. ; Mavligit, Giora M. / The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma. In: Cancer Immunology, Immunotherapy. 1979 ; Vol. 7, No. 2. pp. 131-136.
@article{839c648a1fb94c2b9c1955244772a78f,
title = "The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma",
abstract = "In an attempt improve the response to BCG or BCG + DTIC therapy in Stage IIIB melanoma patients, we added thymosin treatment with repeated doses of 4 mg/m2 or 40 mg/m2. Twenty-eight patients were clinically and immunologically evaluable. Pretreatment immunological evaluation consisted of determination of delayed-type hypersensitivity to recall antigens, enumeration of E-rosettes in blood, and measurement of blood lymphocyte response to phytohemmagglutinin (PHA) and concanavalin A (Con-A). The disease-free interval was correlated with thymosin dose and parameters of immunocompetence. Immunocompetent melanoma patients treated with a high thymosin dose and BCG relapsed earlier than those treated with a low thymosin dose and BCG. Thus, 72{\%} of the melanoma patients who had a PHA SI≥50 and were treated with 4 mg thymosin/m2, were disease-free at 9 months, compared with only 31{\%} of those treated with 40 mg/m2 (P=0.02). When the dermatophytin delayed hypersensitivity response (>10 mm induration) was used as a parameter of immunocompetence, 86{\%} of the patients treated with 4 mg/m2, were disease-free at 9 months, as against 28{\%} of patients treated with 40 mg thymosin/m2 (P=0.07). None of the immunoincompetent patients on high thymosin dose relapsed (0/3). The results suggest that while a high thymosin dose (40 mg/m2) may be detrimental to immunocompetent patients, it may have a beneficial effect in immunoincompetent patients. A low thymosin dose is probably not detrimental to immunocompetent melanoma patients in this study. Monitoring of the immune status prior to and during the use of thymosin in cancer immunotherapy is mandatory.",
author = "Patt, {Yehuda Z.} and Hersh, {Evan M} and Schafer, {Larry A.} and Smith, {Terry L.} and Burgess, {Michael A.} and Gutterman, {Jordan U.} and Goldstein, {Allan L.} and Mavligit, {Giora M.}",
year = "1979",
doi = "10.1007/BF00205335",
language = "English (US)",
volume = "7",
pages = "131--136",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - The need for immune evaluation prior to thymosin-containing chemoimmunotherapy for melanoma

AU - Patt, Yehuda Z.

AU - Hersh, Evan M

AU - Schafer, Larry A.

AU - Smith, Terry L.

AU - Burgess, Michael A.

AU - Gutterman, Jordan U.

AU - Goldstein, Allan L.

AU - Mavligit, Giora M.

PY - 1979

Y1 - 1979

N2 - In an attempt improve the response to BCG or BCG + DTIC therapy in Stage IIIB melanoma patients, we added thymosin treatment with repeated doses of 4 mg/m2 or 40 mg/m2. Twenty-eight patients were clinically and immunologically evaluable. Pretreatment immunological evaluation consisted of determination of delayed-type hypersensitivity to recall antigens, enumeration of E-rosettes in blood, and measurement of blood lymphocyte response to phytohemmagglutinin (PHA) and concanavalin A (Con-A). The disease-free interval was correlated with thymosin dose and parameters of immunocompetence. Immunocompetent melanoma patients treated with a high thymosin dose and BCG relapsed earlier than those treated with a low thymosin dose and BCG. Thus, 72% of the melanoma patients who had a PHA SI≥50 and were treated with 4 mg thymosin/m2, were disease-free at 9 months, compared with only 31% of those treated with 40 mg/m2 (P=0.02). When the dermatophytin delayed hypersensitivity response (>10 mm induration) was used as a parameter of immunocompetence, 86% of the patients treated with 4 mg/m2, were disease-free at 9 months, as against 28% of patients treated with 40 mg thymosin/m2 (P=0.07). None of the immunoincompetent patients on high thymosin dose relapsed (0/3). The results suggest that while a high thymosin dose (40 mg/m2) may be detrimental to immunocompetent patients, it may have a beneficial effect in immunoincompetent patients. A low thymosin dose is probably not detrimental to immunocompetent melanoma patients in this study. Monitoring of the immune status prior to and during the use of thymosin in cancer immunotherapy is mandatory.

AB - In an attempt improve the response to BCG or BCG + DTIC therapy in Stage IIIB melanoma patients, we added thymosin treatment with repeated doses of 4 mg/m2 or 40 mg/m2. Twenty-eight patients were clinically and immunologically evaluable. Pretreatment immunological evaluation consisted of determination of delayed-type hypersensitivity to recall antigens, enumeration of E-rosettes in blood, and measurement of blood lymphocyte response to phytohemmagglutinin (PHA) and concanavalin A (Con-A). The disease-free interval was correlated with thymosin dose and parameters of immunocompetence. Immunocompetent melanoma patients treated with a high thymosin dose and BCG relapsed earlier than those treated with a low thymosin dose and BCG. Thus, 72% of the melanoma patients who had a PHA SI≥50 and were treated with 4 mg thymosin/m2, were disease-free at 9 months, compared with only 31% of those treated with 40 mg/m2 (P=0.02). When the dermatophytin delayed hypersensitivity response (>10 mm induration) was used as a parameter of immunocompetence, 86% of the patients treated with 4 mg/m2, were disease-free at 9 months, as against 28% of patients treated with 40 mg thymosin/m2 (P=0.07). None of the immunoincompetent patients on high thymosin dose relapsed (0/3). The results suggest that while a high thymosin dose (40 mg/m2) may be detrimental to immunocompetent patients, it may have a beneficial effect in immunoincompetent patients. A low thymosin dose is probably not detrimental to immunocompetent melanoma patients in this study. Monitoring of the immune status prior to and during the use of thymosin in cancer immunotherapy is mandatory.

UR - http://www.scopus.com/inward/record.url?scp=0018610553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018610553&partnerID=8YFLogxK

U2 - 10.1007/BF00205335

DO - 10.1007/BF00205335

M3 - Article

AN - SCOPUS:0018610553

VL - 7

SP - 131

EP - 136

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -